- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Wood: Even Treatment Failures Move the Food Allergy Field Forward
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Transcript
What lessons have you learned from the patients and their families in your food allergy studies, even from those that don’t respond to the therapy?
The lessons really are the data that comes from the study for the most part. The families that join studies tend to be highly committed to the entire experience. The kids are remarkably resilient and put up with reactions and food challenges and all those sorts of things.
The knowledge gained is what moves the field forward, and it ranges from tremendous success, where someone is virtually, completely desensitized—not cured, but they can eat food as they wish—to the 15% or so of patients who are complete treatment failures.
And then, long-term the results are, to me, a little bit discouraging. And we’re presenting here at this meeting [2019 AAAAI Annual Meeting], a long-term follow-up of our peanut studies, and over half of all the patients who we thought were successfully treated had electively gone back to strictly avoiding peanuts because they thought life was easier avoiding peanuts than taking a daily dose of peanut.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More
